Trius Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Trius Therapeutics, Inc.
A new outlicensing deal with Viatris will keep it afloat for now but Idorsia needs more time, money and R&D success to secure its long-term future.
With a commercial product ramping up in the US and EU and three Phase III candidates, Idorsia is burning through cash quickly and needs more remedies beyond its 475-person headcount reduction.
Quviviq is to become the first dual orexin receptor antagonist available on the National Health Service. Just over 20,000 people in England could receive treatment with the drug in its first year, says the health technology assessment institute, NICE.
The US company has returned rights to the hypertension product to Idorsia, which was already in the grip of a cash crunch and will now face greater difficulties getting the drug to market.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.